ArticleMolecules (Basel, Switzerland)2025
Gardeniae Fructus Enhances Skin Barrier Function via AHR-Mediated FLG/LOR/IVL Expression.
Article in Molecules (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Gardeniae Fructus (GF), a traditional Chinese medicine rich in iridoids, has demonstrated skin-improving effects. However, its mechanisms for enhancing epidermal barrier function remain unclear. In this study, the iridoids in GF were characterized using UPLC-MS/MS. The improvement in the barrier function by GF was assessed through in vitro experiments and a human efficacy assessment. In addition, the potential targets were predicted through proteomics analysis, molecular docking, and molecular dynamics (MD), and verified in HaCaT cells and three-dimensional epidermal models. Nine iridoids were identified in GF. In vitro, GF effectively promoted cell migration and reduced cell damage and oxidative stress. Proteomics analysis combined with molecular docking and MD simulations predicted that the primary iridoids in GF ameliorate barrier function by binding to the aryl hydrocarbon receptor (AHR) with high affinity and stability. Subsequent validation demonstrated that GF significantly upregulated AHR, filaggrin (FLG), loricrin (LOR), and involucrin (IVL) mRNA and protein expression. A 28-day randomized double-blind human efficacy assessment in subjects with sensitive skin showed that the gel with GF increased stratum corneum hydration, reduced transepidermal water loss (TEWL), and lowered erythema index and lactic acid tingling. These findings suggest that GF enhances the skin barrier via AHR activation-mediated upregulation of barrier proteins, supporting its cosmeceutical potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.